Macrophage-tumor cell interactions regulate the function of nitric oxide
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Tumor cell-macrophage interactions change as the tumor progresses, and the generation of nitric oxide (NO) by the inducible nitric oxide synthase (iNOS) plays a major role in this interplay. In early stages, macrophages employ their killing mechanisms, particularly the generation of high concentrations of NO and its derivative reactive nitrogen species (RNS) to initiate tumor cell apoptosis and destroy emerging transformed cells. If the tumor escapes the immune system and grows, macrophages that infiltrate it are reprogramed in situ by the tumor microenvironment. Low oxygen tensions (hypoxia) and immunosuppressive cytokines inhibit iNOS activity and lead to production of low amounts of NO/RNS, which are pro-angiogenic and support tumor growth and metastasis by inducing growth factors (e.g., VEGF) and matrix metalloproteinases (MMPs). We review here the different roles of NO/RNS in tumor progression and inhibition, and the mechanisms that regulate iNOS expression and NO production, highlighting the role of different subtypes of macrophages and the microenvironment. We finally claim that some tumor cells may become resistant to macrophage-induced death by increasing their expression of microRNA-146a (miR-146a), which leads to inhibition of iNOS translation. This implies that some cooperation between tumor cells and macrophages is required to induce tumor cell death, and that tumor cells may control their fate. Thus, in order to induce susceptibility of tumors cells to macrophage-induced death, we suggest a new therapeutic approach that couples manipulation of miR-146a levels in tumors with macrophage therapy, which relies on ex vivo stimulation of macrophages and their re-introduction to tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 2×
“REVIEW ARTICLE published: 18 June 2013 doi: 10.3389/fphys.2013.00144 Macrophage-tumor cell interactions regulate the function of nitric oxide”
BackgroundMethodInfluentialAlternative activation of macrophages: mechanism and functions
Gordon, S., & Martinez, F. O. (2010) · Immunity · doi:10.1016/j.immuni.2010.05.007 · Cited by 4,197 · cited 2×
“This concept has been extensively reviewed before (Mosser and Edwards, 2008; Murdoch et al., 2008; Martinez et al., 2009; Gordon and Martinez, 2010; Qian and Pollard, 2010) and will be only briefly mentioned here.”
BackgroundNitric oxide synthases: structure, function and inhibition
ALDERTON, W. K., COOPER, C. E., & KNOWLES, R. G. (2001) · Biochemical Journal · doi:10.1042/bj3570593 · Cited by 4,110 · cited 2×
“This work was funded by a grant from the Ministry of Science and Culture in Lower Saxony, Germany and by a grant from the Israel Cancer Association.”
BackgroundMethodAlternative Activation of Macrophages: An Immunologic Functional Perspective
Martinez, F. O., Helming, L., & Gordon, S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132532 · Cited by 2,745 · cited 2×
“This concept has been extensively reviewed before (Mosser and Edwards, 2008; Murdoch et al., 2008; Martinez et al., 2009; Gordon and Martinez, 2010; Qian and Pollard, 2010) and will be only briefly mentioned here.”
BackgroundThe many faces of macrophage activation
Mosser, D. M. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0602325 · Cited by 1,902 · cited 2×
“Regulatory macrophages, a third type of activation, can be activated by TLR and immune complexes, by anti-inflammatory cytokines or mediators (e.g., adenosine), or by phagocytosis of apoptotic cells (Mosser, 2003; Mosser and Edwards, 2008).”
BackgroundThe role of myeloid cells in the promotion of tumour angiogenesis
Murdoch, C., Muthana, M., Coffelt, S. B., & Lewis, C. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2444 · Cited by 1,642 · cited 2×
“This concept has been extensively reviewed before (Mosser and Edwards, 2008; Murdoch et al., 2008; Martinez et al., 2009; Gordon and Martinez, 2010; Qian and Pollard, 2010) and will be only briefly mentioned here.”
BackgroundDe Palma, M., Venneri, M. A., Galli, R., Sergi, L. S., Politi, L. S., Sampaolesi, M., & Naldini, L. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.002 · Cited by 1,311
Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173
Nitric oxide and redox mechanisms in the immune response
Wink, D. A., Hines, H. B., Cheng, R. Y. S., Switzer, C. H., Flores-Santana, W., Vitek, M. P., Ridnour, L. A., & Colton, C. A. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.1010550 · Cited by 765
Functional plasticity of macrophages: reversible adaptation to changing microenvironments
Stout, R. D., & Suttles, J. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0504272 · Cited by 751 · cited 1×
“Thus, macrophages display enormous plasticity (Stout and www.frontiersin.org June 2013 | Volume 4 | Article 144 | 1 Suttles, 2004; Stout et al., 2009), and can shift from one activation mode to another, unlike lymphocytes that remain committed to only one kind of activation.”
BackgroundInterdependence of hypoxic and innate immune responses
Nizet, V., & Johnson, R. S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2607 · Cited by 708
Regulation of the expression of inducible nitric oxide synthase
Pautz, A., Art, J., Hahn, S., Nowag, S., Voss, C., & Kleinert, H. (2010) · Nitric Oxide · doi:10.1016/j.niox.2010.04.007 · Cited by 549
MacLeod (2008) · Bristol Research (University of Bristol) · doi:10.4049/jimmunol · Cited by 448
Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin
Lechner, M., Lirk, P., & Rieder, J. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.04.004 · Cited by 410
Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients
Glynn, S. A., Boersma, B. J., Dorsey, T. H., Yi, M., Yfantis, H. G., Ridnour, L. A., Martin, D. N., Switzer, C. H., Hudson, R. S., Wink, D. A., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42059 · Cited by 254
The biphasic nature of nitric oxide responses in tumor biology
Ridnour, L. A., Thomas, D. D., Donzelli, S., Espey, M. G., Roberts, D. D., Wink, D. A., & Isenberg, J. S. (2006) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.8.1329 · Cited by 247 · cited 3×
“Low levels of NO/RNS can directly and indirectly via VEGF enhance angiogenesis by activating MMP-1, MMP-9, and MMP13 (Ridnour et al., 2007; Ziche and Morbidelli, 2009), MMPs are critical for angiogenesis, as they degrade components of the ECM and pave the way for migration of endothelial cells into…”
BackgroundCoffelt, S. B., Chen, Y.-Y., Muthana, M., Welford, A. F., Tal, A. O., Scholz, A., Plate, K. H., Reiss, Y., Murdoch, C., De Palma, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002802 · Cited by 220
Ridnour, L. A., Windhausen, A. N., Isenberg, J. S., Yeung, N., Thomas, D. D., Vitek, M. P., Roberts, D. D., & Wink, D. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702761104 · Cited by 219
On the expression of nitric oxide synthase by human macrophages. Why no NO?
Albina, J. E. (1995) · Journal of Leukocyte Biology · doi:10.1002/jlb.58.6.643 · Cited by 213 · cited 2×
“This work was funded by a grant from the Ministry of Science and Culture in Lower Saxony, Germany and by a grant from the Israel Cancer Association.”
BackgroundMethodFunctional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages
Stout, R. D., Watkins, S. K., & Suttles, J. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0209073 · Cited by 183 · cited 1×
“Thus, macrophages display enormous plasticity (Stout and www.frontiersin.org June 2013 | Volume 4 | Article 144 | 1 Suttles, 2004; Stout et al., 2009), and can shift from one activation mode to another, unlike lymphocytes that remain committed to only one kind of activation.”
BackgroundSwitzer, C. H., Glynn, S. A., Cheng, R. Y.-S., Ridnour, L. A., Green, J. E., Ambs, S., & Wink, D. A. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0124 · Cited by 141 · cited 11×
“Thus, low amounts of NO/RNS which activate S-nitrosylation of proteins may be a general mechanism to prevent degradation of anti-apoptotic proteins and protect cells from death.”
BackgroundInfluentialLancaster, J. R., & Xie, K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2900 · Cited by 98
Cited by
Gasotransmitters in cancer: from pathophysiology to experimental therapy
Szabo, C. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.1 · Cited by 717
Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors
Andrejeva, G., & Rathmell, J. C. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.06.004 · Cited by 373
Wang, H., Tian, T., & Zhang, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168470 · Cited by 364
Banerjee, S. R., Foss, C. A., Horhota, A., Pullambhatla, M., McDonnell, K., Zale, S., & Pomper, M. G. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.6b01485 · Cited by 54
Das, S., Mukherjee, S., & Ali, N. (2021) · PLOS Pathogens · doi:10.1371/journal.ppat.1009343 · Cited by 45
“In early 80s and 90s multiple attempts of macrophage therapy in cancer, by adoptive transfer of immune reactive macrophages inside the core of the tumors failed and the concept got abandoned [62].”
Background
Metadata
- Authors
- Rahat, M. A., & Hemmerlein, B.
- Venue
- Frontiers in Physiology
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 4
- Pages
- 144-144
- ISSN
- 1664-042X (ISSN-L)
- OpenAlex
- W2049253717
- Cited by
- 109
- References
- 22
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.